Indivior Pharmaceuticals, Inc. INDV Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 81.3%+1.5pp | 80.2%-0.4pp | 80.8%+0.3pp | 82.1%+0.2pp | 79.8%-5.0pp | |
| Operating margin | 25.8%+23.3pp | 21.1%+17.9pp | 19.2%+23.2pp | 18.7%+29.2pp | 2.5%+6.0pp | |
| Net margin | 19.4%+20.0pp | 16.9%+16.3pp | 10.8%+14.7pp | 9.2%+18.0pp | -0.6%+2.4pp | |
| EBITDA margin | 26.5%+22.8pp | 21.9%+17.4pp | 20.3%+23.0pp | 19.8%+29.1pp | 3.7%+5.7pp | |
| Efficiency | ||||||
| Inventory turnover | 37.2×+25.1× | 41×+37.6× | 64.9×+4.5× | 16.8×-26.1× | 12.2×+0.3× | |
| Liquidity | ||||||
| Current ratio | 0.9×— | 0.7×— | 1×— | —— | —— | |
| Quick ratio | 0.9×— | 0.7×— | 1×— | —— | —— | |
| Cash ratio | 0.2×— | 0.2×— | 0.5×— | —— | —— | |
| Leverage | ||||||
| Debt-to-assets | 0.4×— | 0.3×— | 0.3×— | —— | —— | |
| Net debt / EBITDA | 1×— | 0.6×— | -0.4×— | —— | —— | |
| Interest coverage | 8.3×+7.7× | 5.8×+4.9× | 4.4×+5.6× | 4.3×+7.6× | 0.6×+1.8× | |
| Per Share | ||||||
| Book value per share | -$1.12+51.0% | -$0.77+69.8% | -$1.60+31.2% | -$2.04— | -$2.28— | |
| Valuation | ||||||
| Market capitalization | $3.72B+213% | $4.49B+189% | $3.01B+131% | $1.74B-19.8% | $1.19B-58.7% | |
| Enterprise value | $4.05B— | $4.64B— | $2.92B— | —— | —— | |
| Price / earnings | 14.8×— | —— | —— | —— | —— | |
| Price / sales | 2.9×+1.9× | 3.6×+2.3× | 2.5×+1.4× | 1.5×-0.4× | 1×-1.6× | |
| EV / EBITDA | 11.8×— | 17.1×— | 12.2×— | —— | —— | |
| EV / sales | 3.1×— | 3.7×— | 2.5×— | —— | —— | |
| Earnings yield | 6.8%+7.3pp | 4.7%+4.2pp | 4.3%+7.7pp | 6.2%+10.8pp | -0.6%+0.6pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Indivior Pharmaceuticals, Inc. 's profit margins?
- Indivior Pharmaceuticals, Inc. (INDV) runs a 81.3% gross margin and a 25.8% operating margin, with a 19.4% net margin.
- Where do Indivior Pharmaceuticals, Inc. 's ratios come from?
- Every ratio is computed from Indivior Pharmaceuticals, Inc. 's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.